214 related articles for article (PubMed ID: 38066569)
1. Characterization of novel CD19-specific VHHs isolated from a camelid immune library by phage display.
Ganji M; Safarzadeh Kozani P; Rahbarizadeh F
J Transl Med; 2023 Dec; 21(1):891. PubMed ID: 38066569
[TBL] [Abstract][Full Text] [Related]
2. Isolation and Characterization of Single-Domain Antibodies from Immune Phage Display Libraries.
Rossotti MA; Trempe F; van Faassen H; Hussack G; Arbabi-Ghahroudi M
Methods Mol Biol; 2023; 2702():107-147. PubMed ID: 37679618
[TBL] [Abstract][Full Text] [Related]
3. [Construction of camelidae natural nanobody phage dispaly library and screening, production and identification of anti-CD19 nanobody].
Li G; Li Y; Chu Y; Zhang A; Pan J; Wang H; Xu G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Nov; 36(11):1036-1043. PubMed ID: 33210599
[TBL] [Abstract][Full Text] [Related]
4. T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.
Nasiri F; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2023; 14():1063838. PubMed ID: 36875091
[TBL] [Abstract][Full Text] [Related]
5. Identification and in vitro characterization of phage-displayed VHHs targeting VEGF.
Farajpour Z; Rahbarizadeh F; Kazemi B; Ahmadvand D; Mohaghegh M
J Biomol Screen; 2014 Apr; 19(4):547-55. PubMed ID: 24297044
[TBL] [Abstract][Full Text] [Related]
6. Isolation and characterization of antigen-specific alpaca (Lama pacos) VHH antibodies by biopanning followed by high-throughput sequencing.
Miyazaki N; Kiyose N; Akazawa Y; Takashima M; Hagihara Y; Inoue N; Matsuda T; Ogawa R; Inoue S; Ito Y
J Biochem; 2015 Sep; 158(3):205-15. PubMed ID: 25888581
[TBL] [Abstract][Full Text] [Related]
7. An alpaca single-domain antibody (VHH) phage display library constructed by CDR shuffling provided high-affinity VHHs against desired protein antigens.
Tsukahara N; Murakami A; Motohashi M; Nakayama H; Kondo Y; Ito Y; Azuma T; Kishimoto H
Int Immunol; 2022 Jul; 34(8):421-434. PubMed ID: 35689594
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a novel nanobody with SRMV neutralizing activity.
Sun M; Wang C; Luo H; Chen Y; Qu G; Chen J; Li L; Zhang M; Xue Q
Microb Cell Fact; 2024 Feb; 23(1):45. PubMed ID: 38341572
[TBL] [Abstract][Full Text] [Related]
9. Construction of a Humanized Artificial VHH Library Reproducing Structural Features of Camelid VHHs for Therapeutics.
Murakami T; Kumachi S; Matsunaga Y; Sato M; Wakabayashi-Nakao K; Masaki H; Yonehara R; Motohashi M; Nemoto N; Tsuchiya M
Antibodies (Basel); 2022 Jan; 11(1):. PubMed ID: 35225868
[TBL] [Abstract][Full Text] [Related]
10. Development of specific nanobodies (VHH) for CD19 immuno-targeting of human B-lymphocytes.
Banihashemi SR; Hosseini AZ; Rahbarizadeh F; Ahmadvand D
Iran J Basic Med Sci; 2018 May; 21(5):455-464. PubMed ID: 29922424
[TBL] [Abstract][Full Text] [Related]
11. Isolation and characterization of Clostridium difficile toxin-specific single-domain antibodies.
Hussack G; Arbabi-Ghahroudi M; Mackenzie CR; Tanha J
Methods Mol Biol; 2012; 911():211-39. PubMed ID: 22886255
[TBL] [Abstract][Full Text] [Related]
12. Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G.
Kazemi-Lomedasht F; Behdani M; Rahimpour A; Habibi-Anbouhi M; Poshang-Bagheri K; Shahbazzadeh D
Monoclon Antib Immunodiagn Immunother; 2015 Jun; 34(3):201-5. PubMed ID: 26090598
[TBL] [Abstract][Full Text] [Related]
13. Selection of similar single domain antibodies from two immune VHH libraries obtained from two alpacas by using different selection methods.
Li T; Vandesquille M; Bay S; Dhenain M; Delatour B; Lafaye P
Immunol Lett; 2017 Aug; 188():89-95. PubMed ID: 28690185
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of camelid single-domain antibodies against HER2.
Hussack G; Raphael S; Lowden MJ; Henry KA
BMC Res Notes; 2018 Dec; 11(1):866. PubMed ID: 30518413
[TBL] [Abstract][Full Text] [Related]
15. Targeting surface-layer proteins with single-domain antibodies: a potential therapeutic approach against Clostridium difficile-associated disease.
Kandalaft H; Hussack G; Aubry A; van Faassen H; Guan Y; Arbabi-Ghahroudi M; MacKenzie R; Logan SM; Tanha J
Appl Microbiol Biotechnol; 2015 Oct; 99(20):8549-62. PubMed ID: 25936376
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of blocking nanobodies against human CD70.
Zhang X; Liu C; Xie Y; Hu Q; Chen Y; Li J
Acta Biochim Biophys Sin (Shanghai); 2022 Oct; 54(10):1518-1527. PubMed ID: 36239354
[TBL] [Abstract][Full Text] [Related]
17. Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics.
Lyu M; Shi X; Liu X; Liu Y; Zhu X; Liao L; Zhao H; Sun N; Wang S; Chen L; Fan L; Xu Q; Zhu Q; Gao K; Chen H; Zhu Y; Li Z; Guo W; Zheng Y; Gu Y; Liu L; Wang M; Liu Y
Anal Chem; 2022 Jun; 94(22):7970-7980. PubMed ID: 35604850
[TBL] [Abstract][Full Text] [Related]
18. A high affinity and specificity anti-HER2 single-domain antibody (VHH) that targets trastuzumab's epitope with versatile biochemical, biological, and medical applications.
Nikkhoi SK; Heydarzadeh H; Vandavasi VG; Yang G; Louro P; Polunas M; Owji H; Hatefi A
Immunol Res; 2024 Feb; 72(1):103-118. PubMed ID: 37632647
[TBL] [Abstract][Full Text] [Related]
19. High affinity nanobodies against human epidermal growth factor receptor selected on cells by E. coli display.
Salema V; Mañas C; Cerdán L; Piñero-Lambea C; Marín E; Roovers RC; Van Bergen En Henegouwen PM; Fernández LÁ
MAbs; 2016 Oct; 8(7):1286-1301. PubMed ID: 27472381
[TBL] [Abstract][Full Text] [Related]
20. Combining of synthetic VHH and immune scFv libraries for pregnancy-associated glycoproteins ELISA development.
Dormeshkin D; Shapira M; Karputs A; Kavaleuski A; Kuzminski I; Stepanova E; Gilep A
Appl Microbiol Biotechnol; 2022 Aug; 106(13-16):5093-5103. PubMed ID: 35723693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
